Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Wednesday, March 27th. HC Wainwright reiterated a buy rating on shares of Seres Therapeutics in a research note on Friday, February 22nd. Zacks Investment Research upgraded shares of Seres Therapeutics from a hold rating to a buy rating and set a $5.50 price objective on the stock in a research report on Friday, January 4th. Cowen restated a buy rating on shares of Seres Therapeutics in a research report on Friday, February 8th. Finally, Oppenheimer restated a buy rating on shares of Seres Therapeutics in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $13.06.
NASDAQ MCRB opened at $6.90 on Friday. Seres Therapeutics has a 1 year low of $4.42 and a 1 year high of $9.75. The company has a market capitalization of $283.23 million, a price-to-earnings ratio of -2.84 and a beta of 1.85.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.15. Seres Therapeutics had a negative net margin of 350.03% and a negative return on equity of 1,584.13%. The business had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $3.78 million. As a group, equities analysts anticipate that Seres Therapeutics will post -1.79 earnings per share for the current fiscal year.
In other news, EVP Thomas Desrosier sold 5,471 shares of the firm’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total transaction of $31,458.25. Following the sale, the executive vice president now owns 21,525 shares in the company, valued at approximately $123,768.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric D. Shaff sold 4,378 shares of the firm’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total transaction of $25,173.50. Following the sale, the insider now owns 17,220 shares in the company, valued at approximately $99,015. The disclosure for this sale can be found here. Company insiders own 37.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can bought a new position in shares of Seres Therapeutics during the 4th quarter valued at $30,000. Two Sigma Investments LP bought a new position in shares of Seres Therapeutics during the 4th quarter valued at $82,000. Paloma Partners Management Co bought a new position in shares of Seres Therapeutics during the 3rd quarter valued at $147,000. Jefferies Group LLC grew its holdings in shares of Seres Therapeutics by 75.5% during the 3rd quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 9,215 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Seres Therapeutics by 48.8% during the 4th quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 8,895 shares during the last quarter. Hedge funds and other institutional investors own 77.26% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Featured Article: Benefits of owning preferred stock
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.